(Reuters) - Some of AstraZeneca’s biggest investors are calling for a radical shake-up of the drugmaker’s board and executive team, including the replacement of David Brennan as CEO, the Financial Times reported on Monday.
(Reuters) - Some of AstraZeneca’s biggest investors are calling for a radical shake-up of the drugmaker’s board and executive team, including the replacement of David Brennan as CEO, the Financial Times reported on Monday.
